The U.S. Food and Drug Administration (FDA) has granted approval for a novel combination antibiotic, Emblaveo. This unique formulation, combining aztreonam and avibactam, is the first-of-its-kind monobactam/β-lactamase inhibitor mix. Set to be commercially available by the third quarter of 2025, this antibiotic solution aims to provide a therapeutic option for patients who have limited or…